Archive for the ‘United States Department of Health and Human Services’ Category
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]
January 5, 2011
Tags: Anthrax vaccines, Clinical trial, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, Research and development, United States Department of Health and Human Services, fuad el-hibri 
No Comments
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation [...]
July 13, 2010
Tags: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, NATO, United States Department of Health and Human Services, United States. Posted in: Emergent BioSolutions, NATO, North Atlantic Treaty Organization, United States Department of Health and Human Services, Vaccine No Comments